Giá NervGen Pharma Corp (NGENF)

NervGen Pharma Corp. operates as a clinical stage biotech company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.